Search Results for "Saphris"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Saphris. Results 1 to 3 of 3 total matches.
See also: asenapine
In Brief: An Asenapine Patch (Secuado) for Schizophrenia
The Medical Letter on Drugs and Therapeutics • Jan 11, 2021 (Issue 1615)
in a transdermal
formulation in the US. A twice-daily sublingual tablet
formulation of asenapine (Saphris ...
A transdermal formulation of the second-generation
(atypical) antipsychotic asenapine (Secuado – Noven)
has been approved by the FDA for once-daily treatment of
schizophrenia in adults. Asenapine is the first antipsychotic
to become available in a transdermal formulation in the US.
A twice-daily sublingual tablet formulation of asenapine
(Saphris) has been available since 2009.
Lumateperone (Caplyta) for Schizophrenia
The Medical Letter on Drugs and Therapeutics • Jul 27, 2020 (Issue 1603)
/day 10-15 mg once/day 1005.40
Asenapine – Saphris (Allergan) 2.5, 5, 10 mg sublingual tabs 5 mg bid5 ...
The FDA has approved lumateperone (Caplyta —
Intracellular Therapies), an oral second-generation
antipsychotic, for once-daily treatment of schizophrenia
in adults. It is the 13th second-generation antipsychotic
drug to be approved by the FDA for this indication.
Drugs for Bipolar Disorder
The Medical Letter on Drugs and Therapeutics • Apr 01, 2024 (Issue 1699)
306.00
Saphris (Allergan) 1200.80
Cariprazine3,15 – Vraylar (Allergan) 1.5, 3, 4.5, 6 mg caps 1.5 mg ...
Bipolar disorder is characterized by episodes of
mania, hypomania, and depression. Recurrences of
manic or (more frequently) depressive symptoms
are common. About 15-20% of patients with bipolar
disorder die by suicide.
Med Lett Drugs Ther. 2024 Apr 1;66(1699):49-54 doi:10.58347/tml.2024.1699a | Show Introduction Hide Introduction